NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Medical Devices · USD

Abbott Laboratories (ABT) Stock Analysis

Abbott Laboratories (ABT) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

ABT

$100.51

−$1.94 (−1.89%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABT with… →

ABT Key Statistics

As of Oct 21, 2026
Trading
Open
$101.31
Previous Close
$102.45
Day's Range
97.67–106.35
52-Week Range
81.97–132.03
Volume
22.78M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.58
Valuation
Market Cap
$173.92B
P/E Ratio
32.42
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.58
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.88
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.73
EPS (ttm)Profit attributable to each share over the last twelve months.
3.10
Financials (FY)
Revenue (FY)
$44.33B+5.67%
Net Income (FY)
$6.52B−51.32%
Profit marginThe share of revenue left as profit after all costs and taxes.
11.65%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.73B
1-Year Return
−19.23%
Dividend and dates
Dividend
$2.52+2.46%
Ex-Dividend Date
October 15, 2026
Earnings Date
October 21, 2026
Avg Volume
8.83M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ABT closed at $100.51, −19.23% over 1 year.

Abbott Laboratories (ABT) has a market capitalization of $173.92B.

In fiscal 2025, ABT reported revenue of $44.33B.

ABT Stock Return by Calendar Year

Abbott Laboratories (ABT) 10-year return: what $10,000 became

1 year
$10,000 $8,077
−19.23%
5 years
$10,000 $8,879
−11.21%
10 years
$10,000 $29,952
+199.52%

If you had invested $10,000 in Abbott Laboratories (ABT) 10 years ago, at the close on October 21, 2016, it would have been worth $29,952 at the close on October 21, 2026: +199.52% in total, +11.59% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.78%
2025+12.87%
2024+4.81%
2023+2.26%
2022−20.68%
2021+30.53%
2020+28.04%
2019+22.08%
2018+29.06%
2017+52.03%
2016 (partial year)−14.67%

As of October 21, 2026.

ABT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$44.33B$6.52B14.7%
2024$41.95B$13.40B31.9%
2023$40.11B$5.72B14.3%
2022$43.65B$6.93B15.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$44.33B$25.01B$8.05B$6.52B14.7%
2024$41.95B$23.24B$6.83B$13.40B31.9%
2023$40.11B$22.13B$6.48B$5.72B14.3%
2022$43.65B$24.51B$8.36B$6.93B15.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABT Dividend History

$2.36+7.3% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$2.524—
2025$2.364+7.3%
2024$2.204+7.8%
2023$2.044+8.5%
YearDividends per sharePaymentsChange
2026 (partial year)$2.524—
2025$2.364+7.3%
2024$2.204+7.8%
2023$2.044+8.5%
2022$1.884+4.4%
2021$1.804+25.0%
2020$1.444+12.5%
2019$1.284+14.3%
2018$1.124+5.7%
2017$1.064—

Most recent payment: $0.63 per share, ex-dividend October 15, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

ABT Valuation vs Medical Devices Median

Median of 145 stocks
MetricABTMedical Devices medianvs median
P/E32.4227.0820% above
P/S ratio3.732.5348% above
Profit margin11.65%−14.78%26.4 pts above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Abbott Laboratories (ABT) at $173.92B. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 122,000.

The 52-week range on file runs from $81.97 to $132.03. The most recent close on file for ABT is $100.51, dated October 21, 2026. That is −$1.94 (−1.89%) against the previous close. The latest close sits 22.62% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $44.33B. That is +5.67% against the prior fiscal year, when revenue was $41.95B. Net income for the same year was $6.52B. That is −51.32% against the prior fiscal year. Profit margin runs at 11.65%. That is 26.4 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to 3.1.

Across the 4 fiscal years on file, revenue moves from $43.65B in 2022 to $44.33B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

ABT trades at a trailing price-to-earnings ratio of 32.42. That is 19.72% above the Medical Devices median of 27.08. On forward earnings the ratio is 16.58. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.88. The price-to-sales ratio is 3.73. On price-to-sales that is 47.58% above the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.58. Daily returns over the trailing 10 years annualize to a volatility of 23.99%. The trailing one-year total return is −19.23%. Across 10 years the annualized return works out at +11.59%.

Growth & Income

The trailing dividend yield is 2.46%. That is 1.3 percentage points above the Medical Devices median yield of 1.15%. The indicated annual rate is $2.52 a share. The ex-dividend date on file is October 15, 2026. Dividends are recorded for 10 calendar years; 2026 shows 4 payments totalling $2.52 a share. The year before, 2025, totalled $2.36 a share.

So far in 2026 the total return is −17.78%. Across the complete calendar years on file, 2017 returned +52.03% and 2022 returned −20.68%. Of the 9 complete calendar years on file, 8 finished higher.

Peer Comparison

Abbott Laboratories (ABT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8
Boston Scientific Corporation BSX $64.33B 18.0

The Medical Devices industry average P/E ratio is 27.1x. Abbott Laboratories trades at a P/E of 32.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B

 DXCM

DexCom, Inc.

$30.29B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Visit website →